Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ALT-L9 vs Eylea in Neovascular AMD
NCT04058535Phase 1Completed
- Sponsor
- Alteogen
- Start
- Feb 2020
- Primary completion
- Dec 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of alt-l9 in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Alteogen. Primary endpoint: Occurrences of adverse events at 8 weeks. Started Feb 2020; status: completed.
02
Drugs
alt-l9
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04058535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058535.